Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Intal 20mg Spincaps
0303010Q0BBACAD
|
Intal | Sodium cromoglicate | Respiratory System | No data available |
|
Intal 20mg/2ml nebuliser solution unit dose vials
0303010Q0BBAEAE
|
Intal | Sodium cromoglicate | Respiratory System | No data available |
|
Intal 5mg/dose Fisonair with spacer
0303010Q0BBAJAJ
|
Intal | Sodium cromoglicate | Respiratory System | No data available |
|
Intal 5mg/dose inhaler
0303010Q0BBAFAB
|
Intal | Sodium cromoglicate | Respiratory System | No data available |
|
Intal 5mg/dose Syncroner with spacer
0303010Q0BBAKAJ
|
Intal | Sodium cromoglicate | Respiratory System | No data available |
|
Intal Spinhaler
21011000300
|
Intal Spinhaler | Other Appliances | Appliances | No data available |
|
Intanza 15microgram strain vacc inj 0.1ml pfs
1404000H0BQABAI
|
Intanza | Influenza | Immunological Products and Vaccines | No data available |
|
Intanza 9microgram strain vacc inj 0.1ml pre-filled syringes
1404000H0BQAAAH
|
Intanza | Influenza | Immunological Products and Vaccines | No data available |
|
Inteflora 250 capsules
091000000BBWEA0
|
Proprietary compound preparation BNF 0910000 | Other compound vitamin/mineral formulation preparations | Nutrition and Blood | No data available |
|
Integrilin 20mg/10ml solution for injection vials
0209000X0BBAAAA
|
Integrilin | Eptifibatide | Cardiovascular System | No data available |
|
Integrilin 75mg/100ml solution for infusion vials
0209000X0BBABAB
|
Integrilin | Eptifibatide | Cardiovascular System | No data available |
|
Integrin 10mg capsules
0402010N0BBAAAA
|
Integrin | Oxypertine | Central Nervous System | No data available |
|
Integrity Encompass sheath 25mm
22300503030
|
Integrity Encompass sheath 25mm | Incontinence Sheaths | Incontinence Appliances | No data available |
|
Integrity Encompass sheath 30mm
22300503031
|
Integrity Encompass sheath 30mm | Incontinence Sheaths | Incontinence Appliances | No data available |
|
Integrity Encompass sheath 35mm
22300503032
|
Integrity Encompass sheath 35mm | Incontinence Sheaths | Incontinence Appliances | No data available |
|
Intelence 100mg tablets
0503010AFBBAAAA
|
Intelence | Etravirine | Infections | No data available |
|
Intelence 200mg tablets
0503010AFBBABAB
|
Intelence | Etravirine | Infections | No data available |
|
Intelence 25mg tablets
0503010AFBBACAC
|
Intelence | Etravirine | Infections | No data available |
|
Interferon alfa-2a 18million units/0.5ml inj pfs
0802040J0AABGBG
|
Interferon A | Interferon alpha | Malignant Disease and Immunosuppression | No data available |
|
Interferon alfa-2a 18million units/0.6ml inj cartridges
0802040J0AABFBF
|
Interferon A | Interferon alpha | Malignant Disease and Immunosuppression | No data available |
|
Interferon alfa-2a 3million units/0.5ml inj pfs
0802040J0AAAVAV
|
Interferon A | Interferon alpha | Malignant Disease and Immunosuppression | No data available |
|
Interferon alfa-2a 4.5million units/0.5ml inj pfs
0802040J0AAAWAW
|
Interferon A | Interferon alpha | Malignant Disease and Immunosuppression | No data available |
|
Interferon alfa-2a 6million units/0.5ml inj pfs
0802040J0AAAXAX
|
Interferon A | Interferon alpha | Malignant Disease and Immunosuppression | No data available |
|
Interferon alfa-2a 9million units/0.5ml inj pfs
0802040J0AAAYAY
|
Interferon A | Interferon alpha | Malignant Disease and Immunosuppression | No data available |
|
Interferon alfa-2b 10million unit inj vials
0802040J0AAAHAH
|
Interferon A | Interferon alpha | Malignant Disease and Immunosuppression | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.